SynthesisFrontiers in nutrition2025
Nut consumption in chronic kidney disease: a systematic review.
Synthesis in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Nuts possess a beneficial nutritional profile with antioxidant and anti-inflammatory properties, potentially improving health outcomes in chronic kidney disease (CKD) patients. This systematic review evaluates the association between nut intake and lipid profile, inflammation, oxidative stress, blood pressure, and mortality in patients with CKD. Methods: A systematic search was performed in Medline, EMBASE, Scopus, CINAHL, and Cochrane Library databases on 27 May 2024 and repeated on 13 February 2025 without restrictions on date, language, or study type. Results: The search identified 2,521 records, with four studies (three trials, one cohort) involving 1,270 CKD patients meeting the inclusion criteria. The studies were heterogeneous in terms of intervention and biomarkers assessed, and all of them had moderate-to-high risk of bias. Overall the findings indicate positive effects of Brazil nuts and baru almond oil on oxidative stress and inflammation markers, while walnuts reduced LDL cholesterol and blood pressure while posing no risk regarding electrolytes balance. Further, the consumption of total nuts was associated with reduction in all-cause mortality. Conclusion: Our review indicates potential benefits for the inclusion of nuts in the diet of patients with CKD, but further studies are required to translate findings into practice. Systematic review registration: PROSPERO, Registration no CRD42024543880. https://www.crd.york.ac.uk/PROSPERO/view/CRD42024543880.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.